ENOV ENOVIS CORPORATION

Enovis Debuts New Foot & Ankle Offerings at the AOFAS Annual Meeting

Enovis Debuts New Foot & Ankle Offerings at the AOFAS Annual Meeting

New solutions in Percutaneous and Open Bunion procedures, External Fixation, and Patient Specific Instrumentation, will be featured as part of the company’s growing evidence based, high tech portfolio.

Wilmington, DE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Today, Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology company, announced it will showcase new products from its recent acquisitions of Novastep® and the external fixation assets of D.N.E., LLC, along with its new, organically developed Evolve34™ Lapidus Instrumentation, and the new “STAR+ Experience,” Enovis’ Total Ankle System plus patient specific instrumentation (PSI), at the American Orthopaedic Foot & Ankle Society® (AOFAS) annual meeting in Louisville, Kentucky from September 20-23, 2023.

“Enovis™ is dedicated to improving patient outcomes by introducing technologies that solve real issues in the foot and ankle industry,” stated Gary Justak, President and General Manager of Enovis™ Foot and Ankle. “Our recent acquisition of Novastep® and the Pecaplasty® Percutaneous Bunion Correction System will drive outcome improvements with an underserved patient population, and the MIS bunion surgery provides efficiency in the OR for the surgeon, while improving patient recovery times with less pain.1,2,3”

Other offerings being showcased for the first time will be Evolve34™, a bunion solution for Lapidus correction that allows surgeons to dial in deformity correction and select a hardware construct specific for the patient’s needs. Additionally, Enovis will be introducing the all new EF1 External Fixation product line, complimenting the flagship DynaNail® and DynaClip™ offerings in the hindfoot segment.

Enovis™ will also highlight products from its foot and ankle continuum of care including:

  • – MIS Bunion Correction
  • Patient Specific Instrumentation for Total Ankle Replacement
  • Walking Boot
  • A versatile stirrup design that aids in the treatment of posterior tibial tendon dysfunction (PTTD)
  • Bone Stimulation Device

AOFAS attendees have opportunities throughout the week to experience these product offerings firsthand.

  • Visit Enovis Booth #313 in the exhibit hall.
  • Register for a special Wednesday evening event, Meet us at the Winner’s Circle, September 20th from 6:30 - 9:30 p.m. Registration links and more information can be found here:
  • Educational event to hear Tyler Gonzalez, MD, MBA* present “Biomechanical Performance of Static Compression Devices Compared to NiTiNOL Compression Devices in Simulated First Metatarsophalangeal Joint Arthrodesis” on September 23 at 8:00 a.m. This presentation is part of the AOFAS Foot and Ankle Papers Session 5A: Forefoot in Ballroom A on the main level.



*Dr. Gonzalez is a paid consultant of Enovis.

CRO-2023-0229, MK-10279



About Enovis

Enovis Corporation (NYSE: ENOV) is an innovation-driven, medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit .



  1. Lee M, Walsh J, Smith MM, Ling J, Wines A, Lam P. Hallux valgus correction comparing percutaneous chevron/Akin (PECA) and open scarf/Akin osteotomies. Foot Ankle Int. 2017;38(8):838-846. doi:10.1177/1071100717704941
  2. Maffulli N, Longo UG, Oliva F, Denaro V, Coppola C. Bosch osteotomy and scarf osteotomy for hallux valgus correction. Orthop Clin North Am. 2009;40(4):515-524. doi:10.1016/j.ocl.2009.06.003
  3. Lam P, Lee M, Xing J, Di Nallo M. Percutaneous surgery for mild to moderate hallux valgus. Foot Ankle Clin. 2016;21(3):459-477. doi:10.1016/j.fcl.2016.04.001



Media Contact:

Erica Mellema

Enovis

(269) 377-2937

Attachment



EN
18/09/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENOVIS CORPORATION

 PRESS RELEASE

Enovis completes sale of its Dr. Comfort Footcare Solutions business f...

Enovis completes sale of its Dr. Comfort Footcare Solutions business for proceeds of up to $60 million Wilmington, DE, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced the sale of its Dr. Comfort diabetic shoe business to Promus Equity Partners, a multi-family asset management firm based in Chicago, for consideration of up to $60 million in cash, consisting of an upfront payment of $45 million, and up to $15 million payable in the future upon the achievement of certain m...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 13, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: September 11, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 6, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

nsiderInsights Weekly Report: August 30, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch